Asset profile
CPL500036
Small molecule
Evidence outlook · lead readout
NCT05278156 · Schizophrenia
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05278156: The study randomized 189 participants to two CPL500036 doses or placebo and used double blinding, with a clinical symptom measure as its primary endpoint. However, no results or statistical comparison for the primary endpoint are posted, so the study provides a well-controlled but currently inconclusive evidence base.
Also in development:Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.